Targets › B7-H3
2 programs from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jul 2027.
Open in Phaseline: the race on B7-H3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 131I-omburtamab Anti-B7-H3 monoclonal antibody labeled with iodine-131 for radioimmunotherapy | B7-H3 | Phase 2 | Desmoplastic Small Round Cell Tumor | Jul 2027 |
| Memorial Sloan Kettering Cancer Center | 177Lu-DTPA-omburtamab Lutetium-177-labeled anti-B7-H3 monoclonal antibody conjugate | B7-H3 | Phase 1 | Recurrent Medulloblastoma | Jun 2030 |
Desmoplastic Small Round Cell Tumor (1) Recurrent Medulloblastoma (1)
antibody (2)
Memorial Sloan Kettering Cancer Center (2)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.